WHO和我国基本药物目录中神经系统用药收录情况的比较研究  

Comparative Study on the Collection of Nervous System Medicines in Essential Medicine List of WHO and China

作　　者：左玮 孙雯娟 唐筱婉 牛子冉 张波[1] ZUO Wei;SUN Wenjuan;TANG Xiaowan;NIU Ziran;ZHANG Bo(Dept.of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院药剂科

出　　处：《中国药房》2020年第4期397-401,共5页China Pharmacy

基　　金：国家自然科学基金资助项目(No.81601033);中国医学科学院医学与健康科技创新工程项目(No.2017-I2M-1-011)

摘　　要：目的:为优化我国基本药物目录中神经系统用药品种提供参考。方法:查阅历版世界卫生组织(WHO)《基本药物示范目录》(简称WHO EML),对其中神经系统用药的收录情况进行统计分析,并将2017年版WHO EML与我国2018年版《国家基本药物目录》(简称NEML)进行比较。结果:1977-2017年,各版WHO EML中收录的神经系统用药品种数和疾病覆盖范围均变动不大。与2017年版WHO EML相比,我国2018年版NEML中神经系统用药品种更多(54种vs.30种),且覆盖了更多的疾病类型,如痴呆(石杉碱甲)、神经痛(普瑞巴林)等;但同样,对于多发性硬化症、神经痛和痴呆等疾病的治疗,可选择的药物并不多,且存在部分同类药物(作用机制相同或者相似)重复收录和部分药物不良反应严重的问题。结论:建议不断优化和完善国家基本药物目录,适当增加部分治疗神经系统疾病的品种,以提高该类疾病的治疗效果,进一步降低患者负担。OBJECTIVE:To optimize the type of nervous system medicines in National Essential Medicine List of China.METHODS:Various editions of WHO Essential Medicine Model List(WHO EML)were consulted,the collection of nervous system medicines was analyzed statistically,and 2017 edition of WHO EML was compared with 2018 edition of National Essential Medicine List of China(NEML).RESULTS:During 1977-2017,the total number of nervous system medicines and disease coverage included in each edition of WHO EML had little change.Compared with 2017 edition of WHO EML,2018 edition of NEML contained more medicines for nervous system disease(54 medicines vs.30 medicines),and covered more disease types,such as dementia(huperzine A)and neuralgia(pregabalin),etc.However,for the treatment of multiple sclerosis,neuralgia,dementia and other diseases,there were not many medicines to choose,and some similar medicines(with the same or similar mechanism of action)were collected repeatedly and some medicines had serious adverse reaction.CONCLUSIONS:It is suggested that National Essential Medicine List should be continuously optimized and perfected,the varieties of essential medicines for the treatment of nervous system diseases should be increased appropriately,for improving the treatment effect of such diseases and reducing the cost burden of patients.

关 键 词：基本药物 基本药物目录 神经系统疾病 世界卫生组织 中国 比较 

分 类 号：R95[医药卫生—药学]